AN
ANTX.US AN2 Therapeutics Inc
- Market cap
- USD 169M
- P/E
- -
- P/B
- 2.23x
- ROE
- -46.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ANTX.US undervalued?
Graham numberThe Graham number of AN2 Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AN2 Therapeutics Inc fundamental analysis
No fundamental analysis for AN2 Therapeutics Inc yet.
AN2 Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the trea…
Full company profileAN2 Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AN2 Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -77.0K | - | - | - | - |
| Operating Income | -31.1M | -7.28M | -21.6M | -42.3M | -69.6M | -54.6M | -38.1M | -37.5M |
| EBITDA | -5.18M | -7.28M | -21.5M | -43.5M | 4.90M | 3.23M | -35.2M | -35.8M |
| Net Income | -33.8M | -13.6M | -21.5M | -41.5M | -64.7M | -51.3M | -35.2M | -34.9M |
| EPS | -1.80 | -0.73 | -1.15 | -2.70 | -2.74 | -1.72 | -1.16 | -0.76 |
| Balance Sheet | ||||||||
| Total Assets | 5.70M | 4.23M | 65.3M | 103M | 139M | 92.1M | 62.0M | 82.0M |
| Total Liabilities | 887K | 1.48M | 3.41M | 7.19M | 14.0M | 10.2M | 8.89M | 6.45M |
| Shareholders' Equity | 4.81M | 2.75M | 61.9M | 95.4M | 125M | 81.8M | 53.1M | 75.5M |
| Cash & Short-term Investments | 5.60M | 4.07M | 58.6M | 96.1M | 107M | 83.6M | 58.0M | 64.4M |
| Total Debt | 728K | - | - | 53.0K | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -2.49M | -5.36M | -20.5M | -33.5M | -53.3M | -49.3M | -29.8M | -33.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.49M | -5.36M | -20.5M | -33.5M | -53.3M | -49.3M | -29.8M | -33.6M |
| Ratios | ||||||||
| ROE | -702.5% | -494.4% | -34.7% | -43.5% | -51.9% | -62.7% | -66.3% | -46.2% |
| ROA | -593.2% | -321.2% | -32.9% | -40.4% | -46.7% | -55.7% | -56.8% | -42.6% |
| Debt to Equity | 0.15x | - | - | 0.00x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
AN2 Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 1.82M | 0.12 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AN2 Therapeutics Inc
- Insiders 15.90%
- Institutions 78.49%
- Public & others 5.61%
- Shares outstanding 37.9M
- Free float 22.5M
Top funds holding ANTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 853K | 2.26% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 652K | 1.73% | 0.00% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 632K | 1.68% | +0.02% | Aug 2026 |
| apo Medical Opportunities R | 331K | 0.88% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 289K | 0.77% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 222K | 0.59% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 153K | 0.41% | +1.29% | Sep 2026 |
| Fidelity Extended Market Index | 132K | 0.35% | +37.88% | Sep 2026 |
| iShares Micro-Cap ETF | 80.8K | 0.21% | 0.00% | Oct 2026 |
| RIM Global Bioscience EUR | 70.0K | 0.19% | 0.00% | Jul 2026 |
| Schwab Small Cap Index | 64.2K | 0.17% | 0.00% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 61.0K | 0.16% | +105.38% | Sep 2026 |
| Fidelity Total Market Index | 57.9K | 0.15% | -0.05% | Sep 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 57.4K | 0.15% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 49.5K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 48.5K | 0.13% | 0.00% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 40.9K | 0.11% | 0.00% | Oct 2026 |
| Nuveen Small Cap Blend Idx R6 | 35.3K | 0.09% | 0.00% | Aug 2026 |
| Dimensional US Small Cap ETF | 35.3K | 0.09% | 0.00% | Oct 2026 |
| Avantis US Small Cap Equity ETF | 35.1K | 0.09% | 0.00% | Oct 2026 |
Top institutions holding ANTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vivo Capital, LLC | 3.15M | 8.36% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 2.93M | 7.77% | +25.71% | Jun 2026 |
| Millennium Management LLC | 2.32M | 6.14% | +4.33% | Jun 2026 |
| BlackRock Inc | 1.67M | 4.41% | +422.48% | Jun 2026 |
| Spruce Street Capital LP | 1.66M | 4.40% | 0.00% | Jun 2026 |
| Almitas Capital LLC | 1.47M | 3.89% | -0.68% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.24M | 3.28% | +22.51% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.00M | 2.65% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 952K | 2.52% | +513.25% | Jun 2026 |
| Boxer Capital Management, LLC | 749K | 1.98% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 698K | 1.85% | +143.52% | Jun 2026 |
| SummitTX Capital, L.P | 597K | 1.58% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 556K | 1.47% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 552K | 1.46% | -22.72% | Jun 2026 |
| Ameriprise Financial Inc | 537K | 1.42% | -22.86% | Jun 2026 |
| Sio Capital Management, LLC | 530K | 1.40% | -19.37% | Jun 2026 |
| Ally Bridge Group (NY) LLC | 526K | 1.39% | 0.00% | Jun 2026 |
| Prosight Management, LP | 475K | 1.26% | -7.97% | Jun 2026 |
| Woodline Partners LP | 460K | 1.22% | -53.73% | Jun 2026 |
| Aldebaran Capital LLC | 367K | 0.97% | -1.17% | Jun 2026 |
AN2 Therapeutics Inc company profile
- Company name
- AN2 Therapeutics Inc
- Ticker
- ANTX.US
- Exchange
- USA Stocks
- Listed since
- Mar 25, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Fiscal year end
- December
- Address
- 1300 El Camino Real, Menlo Park, CA, United States, 94025
- Phone
- 650 331 9090
- Website
- an2therapeutics.com
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases; and GSK plc for the development of new therapies for TB. AN2 Therapeutics, Inc. was incorporated in 2017 and is headquartered in Menlo Park, California.
AN2 Therapeutics Inc management
10- Mr. Eric E. EasomCo-Founder, CEO, President & Chairman of the Board · born 1968
- Mr. Joseph S. ZakrzewskiCo-Founder & Independent Director · born 1962
- Ms. Lucy O. Day CPACFO, & Principal Financial Officer · born 1960
- Mr. Joshua M. Eizen J.D.Chief Legal Officer, COO & Corporate Secretary · born 1979
- Dr. George Harrison Talbot FACP, M.D.Co-Founder & Senior Clinical Advisor · born 1948
- Dr. Michael R. K. Alley Ph.D.Co-founder & Head of Biology
- Ms. Sarah WilliamsVice President of Controller & Principal Accounting Officer · born 1988
- Dr. Sanjay Chanda Ph.D.Chief Development Officer · born 1966
- Mr. Vince HernandezHead of Research
- Dr. Cameron Trenor M.D.Chief Medical Officer